Roxadustat Improves Psychological Stress and Life Quality of Patients with Uremia During Hemodialysis

Jing Yang, Shi-Hua Shen, Wei-Le Wang, Yi-Ya Wang and Jing-Jing Liu

Background and Objective: Hemodialysis is the most commonly used renal replacement therapy. Roxadustat is a Hypoxia-Inducible Factor (HIF) stabilizer that can be used to treat anaemia in Hemodialysis (HD) patients. This study was designed to explore the role of roxadustat on patients with uremia during hemodialysis. Materials and Methods: Patients with uremia who received hemodialysis were divided into the control group and experimental group. Patients in the experimental group were given roxadustat and those in the control group were given recombinant human erythropoietin. The red blood cell indices and biochemical indices of patients were compared, the self-care ability and psychological stress reaction of patients were observed; nutriture and quality of life after treatment of patients and the total effective rate of the two groups were compared. Results: The levels of red blood cell indices in patients of both groups increased after the treatment and patients in the experimental group had higher levels of these indices than the control group. Versus the control group, the experimental group had reduced inflammation, higher self-care ability scores, lower self-rating anxiety scale and self-rating depression scale scores, better results of nutritional index examination and higher short form-36 health survey scores after treatment (all p<0.05). Conclusion: Roxadustat treatment significantly induces erythropoiesis and improves nutriture, negative emotion, self-care ability and quality of life of patients with uremia undergoing hemodialysis.

View Fulltext Back